Cargando…
Prolastin, a pharmaceutical preparation of purified human α1-antitrypsin, blocks endotoxin-mediated cytokine release
BACKGROUND: α1-antitrypsin (AAT) serves primarily as an inhibitor of the elastin degrading proteases, neutrophil elastase and proteinase 3. There is ample clinical evidence that inherited severe AAT deficiency predisposes to chronic obstructive pulmonary disease. Augmentation therapy for AAT deficie...
Autores principales: | Nita, Izabela, Hollander, Camilla, Westin, Ulla, Janciauskiene, Sabina-Marija |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549028/ https://www.ncbi.nlm.nih.gov/pubmed/15683545 http://dx.doi.org/10.1186/1465-9921-6-12 |
Ejemplares similares
-
Therapy with Plasma Purified Alpha1-Antitrypsin (Prolastin(®)) Induces Time-Dependent Changes in Plasma Levels of MMP-9 and MPO
por: Koepke, Janine, et al.
Publicado: (2015) -
Pharmacokinetic comparability of Prolastin(®)-C to Prolastin(® )in alpha(1)-antitrypsin deficiency: a randomized study
por: Stocks, James M, et al.
Publicado: (2010) -
Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe α1-antitrypsin deficiency
por: Hollander, Camilla, et al.
Publicado: (2007) -
α1-antitrypsin and its C-terminal fragment attenuate effects of degranulated neutrophil-conditioned medium on lung cancer HCC cells, in vitro
por: Zelvyte, Inga, et al.
Publicado: (2004) -
Human mast cells decrease SLPI levels in type II – like alveolar cell model, in vitro
por: Hollander, Camilla, et al.
Publicado: (2003)